No therapies currently exist that can halt the progression of chronic kidney disease in children or restore the ability of kidney cells to filter blood. Recently, researchers at the GOFARR Laboratory ...
The REMODEL study clarified which pathways are responsible for semaglutide’s cardiorenal effects in patients with CKD and type 2 diabetes. Glucagon-like peptide-1 receptor agonists (GLP1-RA) are a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback